These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8748487)

  • 1. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy.
    Reddick WE; Bhargava R; Taylor JS; Meyer WH; Fletcher BD
    J Magn Reson Imaging; 1995; 5(6):689-94. PubMed ID: 8748487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.
    van der Woude HJ; Bloem JL; Verstraete KL; Taminiau AH; Nooy MA; Hogendoorn PC
    AJR Am J Roentgenol; 1995 Sep; 165(3):593-8. PubMed ID: 7645476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging.
    de Baere T; Vanel D; Shapeero LG; Charpentier A; Terrier P; di Paola M
    Radiology; 1992 Nov; 185(2):587-92. PubMed ID: 1410378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping.
    Hanna SL; Parham DM; Fairclough DL; Meyer WH; Le AH; Fletcher BD
    Invest Radiol; 1992 May; 27(5):367-73. PubMed ID: 1582820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
    Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
    Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy.
    Han G; Wang Y; Bi WZ; Wang DJ; Lu SB; Zhang L; Zhao B
    Med Oncol; 2012 Jun; 29(2):1347-53. PubMed ID: 21350876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy.
    Ongolo-Zogo P; Thiesse P; Sau J; Desuzinges C; Blay JY; Bonmartin A; Bochu M; Philip T
    Eur Radiol; 1999; 9(5):907-14. PubMed ID: 10369989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy.
    Fletcher BD; Hanna SL; Fairclough DL; Gronemeyer SA
    Radiology; 1992 Jul; 184(1):243-8. PubMed ID: 1319075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated pixel-by-pixel mapping of dynamic contrast-enhanced MR images for evaluation of osteosarcoma response to chemotherapy: preliminary results.
    Hanna SL; Reddick WE; Parham DM; Gronemeyer SA; Taylor JS; Fletcher BD
    J Magn Reson Imaging; 1993; 3(6):849-53. PubMed ID: 8280973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis.
    Bajpai J; Gamnagatti S; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Safaya R; Bakhshi S
    Pediatr Radiol; 2011 Apr; 41(4):441-50. PubMed ID: 20978754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin.
    Futani H; Fukunaga S; Tsukamoto Y; Terada N; Ono J; Okamoto N; Otsuka Y; Tanizawa T; Tomatsuri M; Yoshiya S
    Anticancer Res; 2012 Mar; 32(3):965-71. PubMed ID: 22399618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
    Lindner NJ; Scarborough MT; Spanier SS; Enneking WF
    J Cancer Res Clin Oncol; 1998; 124(10):575-80. PubMed ID: 9829862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
    Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
    Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
    Miser JS; Pritchard DJ; Rock MG; Shives TC; Gilchrist GS; Smithson WA; Arndt CA; Edmonson JH; Schaid DJ
    Cancer Treat Res; 1993; 62():333-8. PubMed ID: 8096748
    [No Abstract]   [Full Text] [Related]  

  • 17. Synchronous multifocal osteosarcoma: results in twelve patients treated with neoadjuvant chemotherapy and simultaneous resection of all involved bones.
    Bacci G; Picci P; Ferrari S; Mercuri M; Briccoli A; Donati D; Manfrini M; Zanoni A; Forni C; Campanacci M
    Ann Oncol; 1996 Oct; 7(8):864-6. PubMed ID: 8922204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.
    Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z
    Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.